Related references
Note: Only part of the references are listed.Germline genetic contribution to the immune landscape of cancer
Rosalyn W. Sayaman et al.
IMMUNITY (2021)
Immune checkpoint inhibitors and chemotherapy in first-line NSCLC: a meta-analysis
Fausto Petrelli et al.
IMMUNOTHERAPY (2021)
Dendritic cell/cytokine-induced killer cell-based immunotherapy in lung cancer: What we know and future landscape
Monireh Mohsenzadegan et al.
JOURNAL OF CELLULAR PHYSIOLOGY (2020)
Clinical diagnosis and treatment of immune checkpoint inhibitor-associated pneumonitis
Hanping Wang et al.
THORACIC CANCER (2020)
Efficacy and Safety of Pembrolizumab Plus Docetaxel vs Docetaxel Alone in Patients With Previously Treated Advanced Non-Small Cell Lung Cancer The PROLUNG Phase 2 Randomized Clinical Trial
Oscar Arrieta et al.
JAMA ONCOLOGY (2020)
Durvalumab With or Without Tremelimumab vs Standard Chemotherapy in First-line Treatment of Metastatic Non-Small Cell Lung Cancer The MYSTIC Phase 3 Randomized Clinical Trial
Naiyer A. Rizvi et al.
JAMA ONCOLOGY (2020)
A systematic review and meta-analysis of immune-mediated liver dysfunction in non-small cell lung cancer
Lan-Lan Lin et al.
INTERNATIONAL IMMUNOPHARMACOLOGY (2020)
PD-L1 expression and response to pembrolizumab in patients with EGFR-mutant non-small cell lung cancer
Eriko Miyawaki et al.
JAPANESE JOURNAL OF CLINICAL ONCOLOGY (2020)
Atezolizumab in combination with carboplatin plus nab-paclitaxel chemotherapy compared with chemotherapy alone as first-line treatment for metastatic non-squamous non-small-cell lung cancer (IMpower130): a multicentre, randomised, open-label, phase 3 trial
Howard West et al.
LANCET ONCOLOGY (2019)
Immune-related adverse events associated with programmed cell death protein-1 and programmed cell death ligand 1 inhibitors for non-small cell lung cancer: a PRISMA systematic review and meta-analysis
Xiaoying Sun et al.
BMC CANCER (2019)
The immune response-related mutational signatures and driver genes in non-small-cell lung cancer
Hao Chen et al.
CANCER SCIENCE (2019)
Prognostic Impact and Risk Factors of Immune-Related Pneumonitis in Patients With Non-Small-Cell Lung Cancer Who Received Programmed Death 1 Inhibitors
Jun Fukihara et al.
CLINICAL LUNG CANCER (2019)
Risk of Pneumonitis and Pneumonia Associated With Immune Checkpoint Inhibitors for Solid Tumors: A Systematic Review and Meta-Analysis
Qiang Su et al.
FRONTIERS IN IMMUNOLOGY (2019)
Pembrolizumab plus Chemotherapy in Metastatic Non-Small-Cell Lung Cancer
L. Gandhi et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Immune-Related Adverse Events Associated with Immune Checkpoint Blockade
Michael A. Postow et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Cancer immunotherapy using checkpoint blockade
Antoni Ribas et al.
SCIENCE (2018)
The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of non-small cell lung cancer (NSCLC)
Julie R. Brahmer et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2018)
First-Line Atezolizumab plus Chemotherapy in Extensive-Stage Small-Cell Lung Cancer
L. Horn et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Pembrolizumab plus Chemotherapy for Squamous Non-Small-Cell Lung Cancer
L. Paz-Ares et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
The Relative Risk and Incidence of Immune Checkpoint Inhibitors Related Pneumonitis in Patients With Advanced Cancer: A Meta-Analysis
Ke Ma et al.
FRONTIERS IN PHARMACOLOGY (2018)
Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial
Achim Rittmeyer et al.
LANCET (2017)
Nivolumab plus ipilimumab as first-line treatment for advanced non-small-cell lung cancer (CheckMate 012): results of an open-label, phase 1, multicohort study
Matthew D. Hellmann et al.
LANCET ONCOLOGY (2017)
First-Line Nivolumab in Stage IV or Recurrent Non-Small-Cell Lung Cancer
D. P. Carbone et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
PD-1 inhibitors increase the incidence and risk of pneumonitis in cancer patients in a doseindependent manner: a metaanalysis
Jiaying Wu et al.
SCIENTIFIC REPORTS (2017)
Comprehensive Meta-analysis of Key Immune-Related Adverse Events from CTLA-4 and PD-1/PD-L1 Inhibitors in Cancer Patients
Guillermo De Velasco et al.
CANCER IMMUNOLOGY RESEARCH (2017)
Clinical features, diagnostic challenges, and management strategies in checkpoint inhibitor-related pneumonitis
Sarah Chuzi et al.
CANCER MANAGEMENT AND RESEARCH (2017)
Incidence of Pneumonitis With Use of Programmed Death 1 and Programmed Death-Ligand 1 Inhibitors in Non-Small Cell Lung Cancer
Monica Khunger et al.
CHEST (2017)
Immune Checkpoint Inhibitors in Challenging Populations
Douglas B. Johnson et al.
CANCER (2017)
Current state of immunotherapy for non-small cell lung cancer
Jyoti Malhotra et al.
TRANSLATIONAL LUNG CANCER RESEARCH (2017)
PD-1 Inhibitor-Related Pneumonitis in Advanced Cancer Patients: Radiographic Patterns and Clinical Course
Mizuki Nishino et al.
CLINICAL CANCER RESEARCH (2016)
Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trial
Louis Fehrenbacher et al.
LANCET (2016)
Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial
Roy S. Herbst et al.
LANCET (2016)
Carboplatin and pemetrexed with or without pembrolizumab for advanced, non-squamous non-small-cell lung cancer: a randomised, phase 2 cohort of the open-label KEYNOTE-021 study
Corey J. Langer et al.
LANCET ONCOLOGY (2016)
Clinical and pathologic features of lung cancer expressing programmed cell death ligand 1 (PD-L1)
Masaki Shimoji et al.
LUNG CANCER (2016)
Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer
Martin Reck et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
Anti-PD-1 Inhibitor-Related Pneumonitis in Non-Small Cell Lung Cancer
Mizuki Nishino et al.
CANCER IMMUNOLOGY RESEARCH (2016)
Toxicities of the anti-PD-1 and anti-PD-L1 immune checkpoint antibodies
J. Naidoo et al.
ANNALS OF ONCOLOGY (2015)
Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer
Julie Brahmer et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer
H. Borghaei et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
RGMb is a novel binding partner for PD-L2 and its engagement with PD-L2 promotes respiratory tolerance
Yanping Xiao et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2014)
Non-Small Cell Lung Cancer: Epidemiology, Risk Factors, Treatment, and Survivorship
Julian R. Molina et al.
MAYO CLINIC PROCEEDINGS (2012)
The Cochrane Collaboration's tool for assessing risk of bias in randomised trials
Julian P. T. Higgins et al.
BMJ-BRITISH MEDICAL JOURNAL (2011)
The PRISMA Statement for Reporting Systematic Reviews and Meta-Analyses of Studies That Evaluate Health Care Interventions: Explanation and Elaboration
Alessandro Liberati et al.
ANNALS OF INTERNAL MEDICINE (2009)
Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement
David Moher et al.
JOURNAL OF CLINICAL EPIDEMIOLOGY (2009)